Question 1

Why am I gaining weight in my 40s and 50s?

Accepted Answer

Five physiological shifts converge in midlife and any one of them — let alone several — produces weight gain that resists what worked at 30. Insulin sensitivity declines, often invisibly. Sex hormones shift (estrogen redistributes fat to visceral storage in women; testosterone drops reduce lean mass in men). Thyroid function often becomes subclinically suboptimal. Cortisol patterns shift with accumulated stress and disrupted sleep. Sleep architecture itself degrades. Same calories, different metabolism. The honest framing: this is not a willpower failure. It's a physiology question, and physiology is testable.

Question 2

Is GLP-1 weight loss therapy safe?

Accepted Answer

For appropriately selected patients with appropriate monitoring, yes — the safety data on semaglutide and tirzepatide is now substantial. The risk profile includes nausea (common, usually transient), pancreatitis (rare but real, which is why we check baseline lipase), gallbladder issues, and rare cases of medullary thyroid effects (contraindicated for patients with MEN-2 or family history of medullary thyroid cancer). Lean mass loss is a real concern that's managed with protein targeting and resistance training. The “safe vs. unsafe” framing is the wrong frame: it's a powerful medication that requires real clinical monitoring, which is what concierge primary care provides and what most telehealth GLP-1 services don't.

Question 3

What's the difference between semaglutide and tirzepatide?

Accepted Answer

Both are GLP-1 receptor agonists. Tirzepatide also activates the GIP receptor, which appears to produce greater weight loss on average (~20% body weight vs ~15% for semaglutide in head-to-head trials). Tirzepatide also has slightly different metabolic effects and tolerability — some patients tolerate one better than the other. Branded names: semaglutide is Ozempic (diabetes) and Wegovy (weight loss); tirzepatide is Mounjaro (diabetes) and Zepbound (weight loss). We prescribe compounded versions of both via Empower Pharmacy. The choice between them depends on individual response, side effects, cost, and clinical context.

Question 4

Does hormone replacement therapy cause weight gain or help with weight loss?

Accepted Answer

The clinical reality: hormone replacement therapy doesn't directly cause weight gain in most women, and often supports body composition improvement by restoring estrogen's effect on insulin sensitivity, fat distribution, and lean mass preservation. Some women experience initial water retention starting hormone replacement therapy. Some experience appetite changes. Net effect across most patients is neutral-to-favorable for weight and meaningfully positive for body composition (visceral fat decreases, lean mass preserves better). The narrative that “hormone replacement therapy makes you gain weight” is mostly outdated and tied to older oral formulations. Transdermal hormone replacement therapy, properly dosed, is generally weight-neutral or weight-favorable.

Question 5

How does insulin resistance affect weight?

Accepted Answer

Insulin is the body's primary fat-storage hormone. When insulin levels run chronically elevated — which is what insulin resistance produces — the body preferentially stores energy as fat rather than burning it. This makes weight loss disproportionately difficult: caloric restriction alone doesn't lower the storage signal, and exercise alone doesn't fully reverse it. Insulin resistance also drives cravings (especially for refined carbohydrate), disrupts sleep, increases inflammation, and accelerates aging. The reassurance: insulin resistance is highly reversible — usually within 8–12 weeks of targeted intervention (which can include diet adjustment, strength training, sleep, and sometimes medication including GLP-1s or metformin).

Question 6

What is hormonal belly fat?

Accepted Answer

“Hormonal belly fat” is the patient-language term for visceral abdominal fat that accumulates as sex hormones shift in midlife — primarily in women as estrogen declines and in men as testosterone declines. Visceral fat is metabolically different from subcutaneous fat: it produces inflammatory signals, worsens insulin resistance, raises cardiovascular risk, and is harder to lose. The pattern is recognizable: weight that lands at the waist instead of the hips or thighs, often without significant change in eating habits. It responds to addressing the underlying hormonal shift (HRT/TRT where appropriate), insulin sensitivity work, strength training (especially heavy compound lifts), and sometimes GLP-1 therapy.

Question 7

Should I get a continuous glucose monitor (CGM)?

Accepted Answer

For most patients with unexplained weight gain or suspected metabolic dysfunction, a two-week CGM trial is one of the highest-yield diagnostic interventions available. The data reveals glucose response patterns to specific foods, the impact of sleep on glycemic stability, and post-meal glucose spikes that fasting labs miss entirely. Most non-diabetic adults are surprised by what their glucose actually does. We prescribe CGMs as part of the weight management workup when the pattern warrants. The result usually accelerates the right interventions faster than any diet-philosophy debate could.

Question 8

How long do I stay on GLP-1?

Accepted Answer

The honest answer is “long enough for the metabolic and behavioral shifts to consolidate, then we taper and reassess.” There isn't a fixed end date. Many patients stay on GLP-1 therapy at maintenance doses indefinitely. Others taper after 12–18 months once weight has stabilized and lifestyle changes have taken hold. Stopping abruptly often results in weight regain because the underlying physiology that drove the gain in the first place hasn't been addressed independently. The protocol here pairs GLP-1 with strength training, protein targeting, sleep work, and (where applicable) hormone optimization so that the durability of results extends beyond the dose.

Question 9

Compounded vs. branded GLP-1 — which do you prescribe?

Accepted Answer

We prescribe compounded semaglutide and tirzepatide through Empower Pharmacy. Empower's compounded preparations include added B vitamins as a clinical bonus. Branded options (Wegovy, Zepbound, Ozempic, Mounjaro) exist but are rarely covered for weight loss and cost substantially more out of pocket; compounded is the preferred path. Compounded GLP-1s exist in a regulatory framework that depends on FDA shortage status; we monitor that status and adjust prescribing if and when commercial supply normalizes. The clinical effect is comparable.

Question 10

Do you accept insurance? What does this cost?

Accepted Answer

No insurance for visits or workup. Concierge membership is $300/month individually or $570/month per couple. Membership includes the comprehensive metabolic workup, the hour-long visits, ongoing monitoring, and physician access. Compounded GLP-1 medications are out-of-pocket and run roughly $200–$400/month depending on molecule and dose. CGM rental is additional. The honest math: this approach costs more upfront than a telehealth GLP-1 subscription, and delivers a level of workup and monitoring those services structurally can't provide.

Question 11

Can you use GLP-1 and hormone replacement therapy together?

Accepted Answer

Sometimes, yes — they work on different drivers, so for some midlife patients they're used alongside each other rather than as an either/or. GLP-1 therapy acts on appetite and blood-sugar regulation; hormone replacement therapy, where it's indicated, restores estrogen's or testosterone's effect on fat distribution and lean mass. The practical reason they can complement each other: GLP-1's main downside is muscle loss, and preserving lean mass is exactly where hormone optimization and strength training do their work. Whether both are appropriate is a clinical decision that depends on your labs, symptoms, and goals — not a default we apply to everyone.

Question 12

Why does perimenopause make insulin resistance worse?

Accepted Answer

Estrogen helps your cells respond to insulin, so as estrogen becomes erratic and then declines through perimenopause, many women become more insulin resistant — the same meal pushes blood sugar and insulin higher than it once did. Higher insulin favors fat storage, particularly visceral belly fat, and can deepen fatigue and brain fog. It's part of why weight that was never an issue can appear in your 40s without any change in how you eat. The shift shows up on labs like fasting insulin and HbA1c, and a two-week continuous glucose monitor often makes the pattern visible.

Question 13

Is perimenopause weight gain reversible?

Accepted Answer

In most cases the pattern can be improved — though it usually takes more than the calorie-cutting that worked earlier in life. Because midlife weight gain is driven by shifting sex hormones, insulin sensitivity, thyroid, cortisol, and sleep — often several at once — the approach that tends to work is identifying which of those drivers are active and addressing them specifically. For some women that includes hormone replacement therapy; for some, insulin and metabolic work; for some, GLP-1 therapy as one tool inside a larger plan. What rarely works is a single fix aimed at only one of five drivers.

Weight that won’t move.

The 5 drivers — and what we test for each.

Insulin & metabolic

Sex hormones

Thyroid

Cortisol & stress

Sleep architecture

Weight management, as practiced here.

The first visit — sixty minutes on history and pattern.

The comprehensive metabolic panel.

Hormonal optimization where indicated.

GLP-1 weight loss therapy when appropriate.

The adjacent work — because GLP-1 is half the protocol at best.

Practiced in a building older than the prescription pad.

Weight management, answered.

Find what’s actually driving it.